Clinic Roundup
• Ariad Pharmaceuticals Inc., of Cambridge, Mass., said it reached enrollment of 50 percent of the patients planned in its randomized Phase III trial of Iclusig (ponatinib) in adults with newly diagnosed chronic myeloid leukemia (CML).
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.